Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

allogeneic umbilical cord blood-derived HSPCs NLA101

A preparation of universal, off-the-shelf, ex vivo expanded, allogeneic umbilical cord blood (UCB)-derived hematopoietic stem and progenitor cells (HSPCs) that can potentially be used to improve hematopoietic recovery after chemotherapy or hematopoietic cell transplantation (HCT). Upon administration of allogeneic HSPCs NLA101, these cells increase and restore the number of HSPCs, which may prevent or decrease infection and other complications of chemotherapy-induced neutropenia (CIN) or cord blood transplantation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic UCB-derived hematopoietic stem and progenitor cells NLA101
Code name:NLA101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search